HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.

Abstract
Thirty-eight patients with advanced or recurrent squamous cell carcinoma of the cervix no longer amenable to management with surgery and/or radiotherapy were given piperazinedione 9 mg/m2 intravenously every 3 weeks. Five (13%) experienced either complete or partial regression of disease, while 13 (34%) demonstrated stable disease. Responses were relatively short (median 3 months) with responders surviving significantly longer than nonresponders (median 20.3 months vs. 3.0 months, p = 0.01). Adverse effects consisted primarily of myelosuppression (61%) and nausea and vomiting (47%) and generally were mild to moderate and tolerable. The drug has minimal activity and tolerable adverse effects and could be considered for trials of combination chemotherapy in this disease.
AuthorsJ T Thigpen, J Blessing, H D Homesley, L L Adcock
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 6 Issue 4 Pg. 423-6 (Aug 1983) ISSN: 0277-3732 [Print] United States
PMID6688150 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibiotics, Antineoplastic
  • Piperazines
  • 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Topics
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (adverse effects, therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy)
  • Drug Evaluation
  • Female
  • Humans
  • Leukocyte Count
  • Leukopenia (chemically induced)
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Piperazines (adverse effects, therapeutic use)
  • Thrombocytopenia (chemically induced)
  • Uterine Cervical Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: